Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-690514/ FOLFIRI · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-690514 | DRUG | Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more |
| BMS-690514 / FOLFIRI | DRUG | Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos |
| BMS-690514 / FOLFOX | DRUG | Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos |
Inclusion Criteria: * Subjects with advanced or metastatic solid tumors for whom the standard of care is ineffective or inappropriate, with adequate kidney, liver and cardiac function.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-690514 is an investigational small molecule being studied for the treatment of non-small-cell lung carcinoma, breast cancer, and other solid tumors. It is being developed by Bristol-Myers Squibb Company and has reached Phase 2 clinical development for these oncology indications.
BMS-690514 is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not described here.
BMS-690514 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker BMY. The drug is an investigational small molecule in clinical development for oncology indications.
BMS-690514 is in Phase 2 clinical development for non-small-cell lung carcinoma, breast cancer, and other solid tumors. It is investigational and not yet approved by regulatory authorities. All completed clinical trials for the drug are Phase 1 studies.
BMS-690514 has been studied in several completed Phase 1 trials, including NCT00329004 in advanced solid tumors, NCT00420186 with paclitaxel and carboplatin, NCT00479583 with FOLFIRI and FOLFOX, and NCT00516451 in Japanese patients with solid tumors. These trials enrolled a total of 141 participants.
No alternative names for BMS-690514 have been reported. The drug is identified solely by its code name BMS-690514 in clinical trial records and development information.